Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, DARA Biosciences's Enterprise Value is $18.77 Mil.
DARA Biosciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2015 was $-10.21 Mil. Therefore, DARA Biosciences's EV-to-EBIT ratio for today is -1.84.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, DARA Biosciences's Enterprise Value is $18.77 Mil.
DARA Biosciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2015 was $-9.53 Mil. Therefore, DARA Biosciences's EV-to-EBITDA ratio for today is -1.97.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, DARA Biosciences's Enterprise Value is $18.77 Mil.
DARA Biosciences's Revenue for the trailing twelve months (TTM) ended in Sep. 2015 was $3.54 Mil. Therefore, DARA Biosciences's EV-to-Revenue ratio for today is 5.30.
DARA Biosciences Enterprise Value Historical Data
The historical data trend for DARA Biosciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of DARA Biosciences's Enterprise Value
For the Biotechnology subindustry, DARA Biosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DARA Biosciences's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DARA Biosciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where DARA Biosciences's Enterprise Value falls into.
DARA Biosciences Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
DARA Biosciences's Enterprise Value for the fiscal year that ended in Dec. 2014 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DARA Biosciences (NAS:DARA) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
DARA Biosciences's current Enterprise Value is $18.77 Mil.
DARA Biosciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.21 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
DARA Biosciences's current Enterprise Value is $18.77 Mil.
DARA Biosciences's EBITDA for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.53 Mil.
DARA Biosciences's current Enterprise Value is $18.77 Mil.
DARA Biosciences's Revenue for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DARA Biosciences Enterprise Value Related Terms
Thank you for viewing the detailed overview of DARA Biosciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
DARA Biosciences (DARA Biosciences) Business Description
DARA Biosciences Inc was incorporated on June 22, 2002. It is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. Through its acquisition of Oncogenerix, Inc., which occurred on January 17, 2012, the Company acquired exclusive U.S. marketing rights to its first commercial proprietary product, Soltamox (oral liquid tamoxifen). The Company's main focus is on the development and commercialization of oncology treatment and supportive care pharmaceutical products: Soltamox, Gemcitabine and other generic sterile injectable cytotoxic products, and Cancer support therapeutics. Soltamox (oral liquid tamoxifen), its first proprietary, FDA approved product, is a drug primarily used to treat breast cancer. Soltamox has been approved by the U.S. Food and Drug Administration ('FDA') for the treatment of breast cancer. Soltamox will be the only liquid formulation of tamoxifen available for sale in the United States. Soltamox is used mainly for the chronic treatment of breast cancer or for cancer prevention in certain susceptible breast cancer subgroups. The Company is also focusing on the development and commercialization of generic sterile injectable cytotoxic products. The Company's agreement with Uman Pharma Inc. pursuant to which it received an exclusive license to import, sell, market and distribute Uman's gemcitabine lyophilized powder product in 200mg and 1g dosage sizes in the U.S. Gemcitabine went off patent in 2011 in the U.S. and is prescribed as first-line therapy for ovarian, breast, lung and pancreatic cancers. Currently, the Company has two main drug candidates advancing through clinical development with cleared Investigational New Drug applications from the FDA: KRN5500, a novel, non-narcotic/non-opioid for the treatment of neuropathic pain in patients with cancer; and DB959, a first-in-class drug candidate for the treatment of type 2 diabetes and dyslipidemia. The Company mainly competes with other pharmaceutical companies, biotechnology companies and other research and academic institutions. The Company's advertising, marketing and distribution of pharmaceutical products in the United States is subject to the regulation of United States Food, Drug and Cosmetic Act.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DARA has been successfully added to your 